Clinical Trials Logo
  1. Home
  2. Advanced Gastric Cancer
  3. NCT04890392

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer Clinical Trial

Official title:
A Single-arm Exploratory Study of Safety and Efficacy of Tislelizumab in Combination With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Cancer

Clinical Trial Summary

At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research hotspot in the academic community. In Asia, Siewert type II and type III are the main types of advanced gastric/gastroesophageal junction cancer. The current consensus in the academic community for the treatment of this part of the tumor is based on the principles of diagnosis and treatment of gastric cancer, of which the value of neoadjuvant therapy in this part of the tumor has been paid more and more attention by scholars. However, there is no highly recognized neoadjuvant therapy. The current situation will promote the development of advanced gastric/gastroesophageal junction cancer to accurate preoperative staging, more accurate population screening, more accurate targets and molecular markers. Immunotherapy is a promising application in oncology. Several PD1/PD-L1 monoclonal antibodies are approved by FDA for the clinical treatment of melanoma and other tumors. Previous clinical studies have shown that PD1/PD-L1 has limited efficacy in digestive tract tumors. However, on ASCO in 2020, Asian analysis of KEYNOTE-062 study showed that in HER-2 negative advanced gastric cancer with PD-1 combined positive score (CPS) ≥ 1 and CPS ≥ 10, the OS of PD-1 inhibitor treatment was superior to that of chemotherapy group, with 24-month OS rate (CPS ≥ 1, 45% VS 23%, CPS ≥ 10, 54% VS 27%). Meanwhile, the results of PACIFIC study phase III clinical trial showed that the 3-year OS of PD-L1 monoclonal antibody combined with radiotherapy in advanced unresectable lung cancer was as high as 57%, which is expected to completely rewrite its clinical practice. Immunotherapy is promising in cancer therapy. This study intends to use immunotherapy combined with SOX (S-1 + Oxaliplatin) as a neoadjuvant therapy for advanced gastric/gastroesophageal junction cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04890392
Study type Interventional
Source Wuhan Union Hospital, China
Contact
Status Recruiting
Phase Phase 2
Start date January 15, 2021
Completion date February 28, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Completed NCT00821990 - Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer Phase 3
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT01248403 - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase 3
Not yet recruiting NCT01206218 - Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT01851941 - A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer Phase 2
Completed NCT00976768 - Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin Phase 2
Active, not recruiting NCT03223376 - A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) Phase 3
Completed NCT03609359 - Lenvatinib and Pembrolizumab Simultaneous Combination Study Phase 2
Completed NCT03350477 - Bioinformation Therapy for Gastric Cancer Phase 2/Phase 3
Completed NCT02935634 - A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Phase 2
Active, not recruiting NCT03579784 - Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer Phase 2
Completed NCT02952729 - Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Phase 1
Recruiting NCT02072317 - Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Phase 2
Completed NCT01503372 - FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer Phase 2
Completed NCT01472250 - A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China N/A
Terminated NCT01402401 - Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients Phase 2
Recruiting NCT01015339 - Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 3
Completed NCT01441336 - Laparoscopic Gastrectomy for Advanced Gastric Cancer Phase 2
Completed NCT02071043 - Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis Phase 2